1,2-Dimethoxy-4-neopentylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-Dimethoxy-4-neopentylbenzene
• 英文别名: 4-(2,2-Dimethylpropyl)-1,2-dimethoxybenzene
• 化学式: C₁₃H₂₀O₂
• 分子量: 208.301
• InChiKey: QLCAPWBQHOMMSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3,4-Dimethoxybenzyl pivalate 以25%的产率得到
  参考文献：
  名称：

  Pincock J.A., Wedge P.J., J. Org. Chem., 59 (1994) N 19, 5587-5595

  摘要：

  DOI：

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Blaney Jeffrey

  公开号：US20120022043A1

  公开（公告）日：2012-01-26

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

  该发明提供了Formula Ia的JAK激酶抑制剂，其对映体、二对映体或其药学上可接受的盐，其中R1、R2、R7和Z在此处定义，包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
• SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS
  申请人：MERLA Beatrix

  公开号：US20090005427A1

  公开（公告）日：2009-01-01

  Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH 2 , CH═CH, CH 2 CH 2 , CH 2 CH═CH or CH 2 CH 2 CH 2 ; R 1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C 1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R 2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C 1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R 3 and R 4 independently denote H; C 1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R 3 and R 4 do not simultaneously mean H; or R 3 and R 4 together denote CH 2 CH 2 OCH 2 CH 2 , or (CH 2 ) 3-6 . The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.

  将与式I对应的氧代二唑化合物替换为：其中X表示CH、CH2、CH═CH、 、 CH═CH或 ；R1表示芳基或杂环基，每种情况下未取代或单取代或多取代；或者与芳基或杂环基连接的C1-3烷基基团，每种情况下未取代或单取代或多取代；R2表示芳基或杂环基，每种情况下未取代或单取代或多取代；连接有C1-3烷基链的芳基基团，每种情况下未取代或单取代或多取代；R3和R4独立地表示H；C1-6烷基，每种情况下饱和或不饱和，支链或直链，其中R3和R4不同时表示H；或者R3和R4一起表示 O ，或( )3-6。这些化合物对μ-阿片受体具有亲和力，可能采取消旋体的形式；对映异构体、二对映异构体、对映异构体或二对映异构体的混合物、单个对映异构体或二对映异构体、游离碱或与生理上可接受的酸形成盐。
• Heterocyclic Compounds and Methods of Use
  申请人：Medivation Technologies, Inc.

  公开号：US20180028518A1

  公开（公告）日：2018-02-01

  This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.

  本公开提供了化合物和使用这些化合物治疗肝纤维化的方法，包括作为非酒精性脂肪性肝炎（NASH）的前体、与NASH同时发生、与NASH相关或次生于NASH的肝纤维化的治疗方法；高胆固醇水平和胰岛素抵抗。
• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS
  申请人：National Taiwan University

  公开号：US20140080848A1

  公开（公告）日：2014-03-20

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。